» Articles » PMID: 38249738

ATP13A2 (PARK9) and Basal Ganglia Function

Overview
Journal Front Neurol
Specialty Neurology
Date 2024 Jan 22
PMID 38249738
Authors
Affiliations
Soon will be listed here.
Abstract

ATP13A2 is a lysosomal protein involved in polyamine transport with loss of function mutations associated with multiple neurodegenerative conditions. These include early onset Parkinson's disease, Kufor-Rakeb Syndrome, neuronal ceroid lipofuscinosis, hereditary spastic paraplegia, and amyotrophic lateral sclerosis. While mutations may result in clinical heterogeneity, the basal ganglia appear to be impacted in the majority of cases. The basal ganglia is particularly vulnerable to environmental exposures such as heavy metals, pesticides, and industrial agents which are also established risk factors for many neurodegenerative conditions. Not surprisingly then, impaired function of ATP13A2 has been linked to heavy metal toxicity including manganese, iron, and zinc. This review discusses the role of ATP13A2 in basal ganglia function and dysfunction, potential common pathological mechanisms in ATP13A2-related disorders, and how gene x environment interactions may contribute to basal ganglia dysfunction.

Citing Articles

Iron Dyshomeostasis in Neurodegeneration with Brain Iron Accumulation (NBIA): Is It the Cause or the Effect?.

Agostini F, Sgalletta B, Bisaglia M Cells. 2024; 13(16).

PMID: 39195264 PMC: 11352641. DOI: 10.3390/cells13161376.


Association between inflammatory bowel disease and osteoporosis in European and East Asian populations: exploring causality, mediation by nutritional status, and shared genetic architecture.

Kang J, Wu X, Li Y, Zhao S, Wang S, Yu D Front Immunol. 2024; 15:1425610.

PMID: 39136019 PMC: 11317921. DOI: 10.3389/fimmu.2024.1425610.


Involvement of mammalian SoLute Carriers (SLC) in the traffic of polyamines.

Pochini L Front Mol Biosci. 2024; 11:1452184.

PMID: 39130372 PMC: 11310933. DOI: 10.3389/fmolb.2024.1452184.


Nigral ATP13A2 depletion induces Parkinson's disease-related neurodegeneration in a pilot study in non-human primates.

Sikora J, Dovero S, Kinet R, Arotcarena M, Bohic S, Bezard E NPJ Parkinsons Dis. 2024; 10(1):141.

PMID: 39090150 PMC: 11294619. DOI: 10.1038/s41531-024-00757-4.

References
1.
Schenck J, Zimmerman E . High-field magnetic resonance imaging of brain iron: birth of a biomarker?. NMR Biomed. 2004; 17(7):433-45. DOI: 10.1002/nbm.922. View

2.
Schneider S, Dusek P, Hardy J, Westenberger A, Jankovic J, Bhatia K . Genetics and Pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA). Curr Neuropharmacol. 2013; 11(1):59-79. PMC: 3580793. DOI: 10.2174/157015913804999469. View

3.
Ramirez A, Heimbach A, Grundemann J, Stiller B, Hampshire D, Cid L . Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet. 2006; 38(10):1184-91. DOI: 10.1038/ng1884. View

4.
Park J, Mehta P, Cooper A, Veivers D, Heimbach A, Stiller B . Pathogenic effects of novel mutations in the P-type ATPase ATP13A2 (PARK9) causing Kufor-Rakeb syndrome, a form of early-onset parkinsonism. Hum Mutat. 2011; 32(8):956-64. DOI: 10.1002/humu.21527. View

5.
Lewandowski N, Ju S, Verbitsky M, Ross B, Geddie M, Rockenstein E . Polyamine pathway contributes to the pathogenesis of Parkinson disease. Proc Natl Acad Sci U S A. 2010; 107(39):16970-5. PMC: 2947879. DOI: 10.1073/pnas.1011751107. View